{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:19Z","timestamp":1789578139555,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although the majority of indolent lymphomas (focusing on follicular lymphoma [FL]) have a prolonged waxing and waning course, a portion of patients experience histologic transformation (HT) to either diffuse large B-cell lymphoma or a higher-grade morphology, often with acquisition of MYC and BCL2 and\/or BCL6 rearrangements (high-grade B-cell lymphoma\u2013double-hit lymphoma\/triple-hit lymphoma). The overall incidence of HT and transformed follicular lymphoma (tFL) may be declining, but outcomes remain inferior to those in simple indolent lymphoma progression. Recent data suggest that the majority of HT cases occur in higher-risk patients with FL, and they occur early after initial chemoimmunotherapy, comprising the majority of patients with progression of disease within 24 months. This latter point emphasizes the need for a sufficient biopsy at relapse in FL. Treatment options depend on the prior therapy for the indolent component as well as the histology at relapse, but they generally follow several principles discussed in this article. Anthracycline-na\u00efve patients have the best outcomes if there is HT, and responses to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) are similar to those of patients with de novo diffuse large B-cell lymphoma. Patients with anthracycline exposure prior to transformation have the best outcomes with salvage chemotherapy and a consolidative autologous stem cell transplant. However, a major challenge is the management of patients with tFL who experience relapse early after bendamustine-based treatment, in whom the role of consolidative transplant after anthracycline-based treatment is unclear. In the past several years, cellular therapy has emerged as an important tool for some but not all patients with tFL. This review focuses on the nuances of managing tFL.<\/jats:p>","DOI":"10.1182\/hematology.2020000115","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:09:22Z","timestamp":1607137762000},"page":"306-311","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Transformed lymphoma: what should I do now?"],"prefix":"10.1182","volume":"2020","author":[{"given":"Sonali","family":"Smith","sequence":"first","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"26","key":"2020121621163134500_B1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020121621163134500_B2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020121621163134500_B3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2020121621163134500_B4","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial [published correction appears in J Clin Oncol. 2016;34(26):3230.]","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020121621163134500_B5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"8","key":"2020121621163134500_B6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"32","key":"2020121621163134500_B7","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020121621163134500_B8","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study [published correction appears in J Clin Oncol. 2016;34(12):1430]","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020121621163134500_B9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2020121621163134500_B10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.2019001091","article-title":"Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study","volume":"135","author":"Mir","year":"2020","journal-title":"Blood"},{"issue":"16","key":"2020121621163134500_B11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2019000858","article-title":"Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2020121621163134500_B12","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1080\/10428194.2016.1265114","article-title":"Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013","volume":"58","author":"Gleeson","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2020121621163134500_B13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdu537","article-title":"Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation","volume":"26","author":"Madsen","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"2020121621163134500_B14","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.3324\/haematol.2016.144550","article-title":"Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas","volume":"101","author":"Kansara","year":"2016","journal-title":"Haematologica"},{"key":"2020121621163134500_B15","article-title":"Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma [published online ahead of print 6 July 2020]","author":"Chin","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020121621163134500_B16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"2020121621163134500_B17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.2601","article-title":"Transformed follicular lymphoma in the rituximab era: a report from the Spanish Lymphoma Oncology Group","volume":"37","author":"M\u00e9ndez","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"2020121621163134500_B18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood-2015-01-622084","article-title":"Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12","volume":"126","author":"Kuruvilla","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2020121621163134500_B19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbmt.2014.03.014","article-title":"Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma","volume":"20","author":"Wirk","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020121621163134500_B20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2020121621163134500_B21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020121621163134500_B22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"27","key":"2020121621163134500_B23","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020121621163134500_B24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","article-title":"The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin","volume":"154","author":"Czuczman","year":"2011","journal-title":"Br J Haematol"},{"issue":"9","key":"2020121621163134500_B25","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2020121621163134500_B26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020121621163134500_B27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020121621163134500_B28","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2020121621163134500_B29","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020121621163134500_B30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bjh.16319","article-title":"Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy","volume":"189","author":"Landsburg","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/306\/1794823\/hem2020000115c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/306\/1794823\/hem2020000115c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:11:50Z","timestamp":1608315110000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/306\/474282\/Transformed-lymphoma-what-should-I-do-now"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000115","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}